Literature DB >> 26991680

In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T.

Sandeep K Ganji1, Zhongxu An1, Vivek Tiwari1, Sarah McNeil2,3, Marco C Pinho1,4, Edward Pan2,5,6, Bruce E Mickey2,3,6, Elizabeth A Maher2,3,5,7, Changho Choi1,2,4.   

Abstract

PURPOSE: To test the efficacy of 7T MRS for in vivo detection of 2-hydroxyglutarate (2HG) in brain tumors.
METHODS: The subecho times of point-resolved spectroscopy (PRESS) were optimized at 7T with density-matrix simulations and phantom validation to improve the 2HG signal selectivity with respect to the neighboring resonances of γ-aminobutyric acid (GABA), glutamate (Glu), and glutamine (Gln). MRS data were acquired from 12 subjects with gliomas in vivo and analyzed with LCModel using calculated basis spectra. Metabolite levels were quantified using unsuppressed short echo time (TE) water as a reference.
RESULTS: The PRESS TE was optimized as TE = 78 ms (TE1 = 58 ms and TE2 = 20 ms), at which the 2HG 2.25 ppm resonance appeared as a temporally maximum inverted narrow peak and the GABA, Glu, and Gln resonances between 2.2 and 2.5 ppm were all positive peaks. The PRESS TE = 78 ms method offered improved discrimination of 2HG from Glu, Gln, and GABA when compared with short-TE MRS. 2HG was detected in all patients enrolled in the study, the estimated 2HG concentrations ranging from 1.0 to 6.2 mM, with percentage standard deviation of 2%-7%.
CONCLUSION: Data indicate that the optimized MRS provides good selectivity of 2HG from other metabolite signals and may confer reliable in vivo detection of 2HG at relatively low concentrations. Magn Reson Med 77:936-944, 2017.
© 2016 International Society for Magnetic Resonance in Medicine. © 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  1H MRS; 2-hydroxyglutarate (2HG); 7T, PRESS (point-resolved spectroscopy); IDH (isocitrate dehydrogenase); gliomas; human brain tumors

Mesh:

Substances:

Year:  2016        PMID: 26991680      PMCID: PMC5026542          DOI: 10.1002/mrm.26190

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  28 in total

1.  Proton T2 relaxation study of water, N-acetylaspartate, and creatine in human brain using Hahn and Carr-Purcell spin echoes at 4T and 7T.

Authors:  Shalom Michaeli; Michael Garwood; Xiao-Hong Zhu; Lance DelaBarre; Peter Andersen; Gregor Adriany; Hellmut Merkle; Kamil Ugurbil; Wei Chen
Journal:  Magn Reson Med       Date:  2002-04       Impact factor: 4.668

2.  Improvement of resolution for brain coupled metabolites by optimized (1)H MRS at 7T.

Authors:  Changho Choi; Ivan E Dimitrov; Deborah Douglas; Aditya Patel; Lana G Kaiser; Carlos A Amezcua; Elizabeth A Maher
Journal:  NMR Biomed       Date:  2010-11       Impact factor: 4.044

3.  Detection of glutamate, glutamine, and glutathione by radiofrequency suppression and echo time optimization at 7 tesla.

Authors:  Li An; Shizhe Li; James B Murdoch; Maria Ferraris Araneta; Christopher Johnson; Jun Shen
Journal:  Magn Reson Med       Date:  2014-02-28       Impact factor: 4.668

4.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Methodology for improved detection of low concentration metabolites in MRS: optimised combination of signals from multi-element coil arrays.

Authors:  Emma L Hall; Mary C Stephenson; Darren Price; Peter G Morris
Journal:  Neuroimage       Date:  2013-04-29       Impact factor: 6.556

7.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

Review 9.  Metabolic consequences of oncogenic IDH mutations.

Authors:  Seth J Parker; Christian M Metallo
Journal:  Pharmacol Ther       Date:  2015-05-05       Impact factor: 13.400

10.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714

View more
  22 in total

1.  Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression.

Authors:  Ankita Bansal; Danielle J Sanchez; Vivek Nimgaonkar; David Sanchez; Romain Riscal; Nicolas Skuli; M Celeste Simon
Journal:  Mol Cancer Res       Date:  2019-05-31       Impact factor: 5.852

2.  Ultrahigh field MR Neuroimaging.

Authors:  Gaurav Verma; Priti Balchandani
Journal:  Top Magn Reson Imaging       Date:  2019-06

3.  High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T.

Authors:  Gilbert Hangel; Saurabh Jain; Elisabeth Springer; Eva Hečková; Bernhard Strasser; Michal Považan; Stephan Gruber; Georg Widhalm; Barbara Kiesel; Julia Furtner; Matthias Preusser; Thomas Roetzer; Siegfried Trattnig; Diana M Sima; Dirk Smeets; Wolfgang Bogner
Journal:  Neuroimage       Date:  2019-02-14       Impact factor: 6.556

4.  Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

Authors:  Zhongxu An; Vivek Tiwari; Sandeep K Ganji; Jeannie Baxter; Michael Levy; Marco C Pinho; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2017-08-22       Impact factor: 4.668

5.  Phase-encoded single-voxel magnetic resonance spectroscopy for suppressing outer volume signals at 7 Tesla.

Authors:  Ningzhi Li; Li An; Christopher Johnson; Jun Shen
Journal:  Biomed Spectrosc Imaging       Date:  2017-12-27

6.  Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.

Authors:  Elavarasan Subramani; Marina Radoul; Chloe Najac; Georgios Batsios; Abigail R Molloy; Donghyun Hong; Anne Marie Gillespie; Romelyn Delos Santos; Pavithra Viswanath; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Cancer Res       Date:  2020-09-21       Impact factor: 12.701

7.  Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning.

Authors:  Sahil Nalawade; Gowtham K Murugesan; Maryam Vejdani-Jahromi; Ryan A Fisicaro; Chandan G Bangalore Yogananda; Ben Wagner; Bruce Mickey; Elizabeth Maher; Marco C Pinho; Baowei Fei; Ananth J Madhuranthakam; Joseph A Maldjian
Journal:  J Med Imaging (Bellingham)       Date:  2019-12-10

8.  In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Authors:  Valeria Cuccarini; Luigi Antelmi; Bianca Pollo; Rosina Paterra; Chiara Calatozzolo; Anna Nigri; Francesco DiMeco; Marica Eoli; Gaetano Finocchiaro; Greta Brenna; Irene Tramacere; Maria Grazia Bruzzone; Elena Anghileri
Journal:  Neurol Sci       Date:  2019-10-24       Impact factor: 3.307

9.  In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.

Authors:  Vivek Tiwari; Tomoyuki Mashimo; Zhongxu An; Vamsidhara Vemireddy; Sara Piccirillo; Pegah Askari; Keith M Hulsey; Shanrong Zhang; Robin A de Graaf; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Robert M Bachoo; Changho Choi
Journal:  Magn Reson Med       Date:  2020-01-30       Impact factor: 4.668

10.  Spectral editing in 1 H magnetic resonance spectroscopy: Experts' consensus recommendations.

Authors:  In-Young Choi; Ovidiu C Andronesi; Peter Barker; Wolfgang Bogner; Richard A E Edden; Lana G Kaiser; Phil Lee; Małgorzata Marjańska; Melissa Terpstra; Robin A de Graaf
Journal:  NMR Biomed       Date:  2020-09-18       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.